Abbott Laboratories Corporation

Abbvie Inc.

Abbott Gmbh & Co Kg

Abbvie Deutschland Gmbh and Co Kg

John E Harlan

Ulrich Ebert

Chung-Ming Hsieh

Jijie Gu

Martin Schmidt

Reinhold Mueller

Volker Nimmrich

Enrico L Digiammarino

Gerard B Fox

Ralf Loebbert

Feng Luo

Zhen Wu

Andrew J Souers

Boris Labkovsky

Heinz Hillen

Lorenzo Benatuil

Stefan Barghorn

Erwin R Boghaert

Gillian A Kingsbury

Andrew C Phillips

Bradford L McRae

Edward T Olejniczak

Ana Pereda-Lopez

Thomas F Holzman

Kamel Izeradjene

Rui Wang

Rohinton P Edalji

Russell A Judge

Liping Yu

The present disclosure relates to anti-Epidermal Growth Factor Receptor (EGFR) antibody drug conjugates (ADCs) which inhibit Bcl-xL, including compositions and methods using such ADCs, and methods for making such ADCs.

Anti-EGFR antibody-drug conjugates

The present application relates to isolated proteins, particularly monoclonal antibodies, in particular CDR-grafted, humanized antibodies which bind to RAGE protein. Specifically, these antibodies have the ability to inhibit the binding of RAGE to its various ligands. The antibodies or portions thereof of described in the present application are useful for treating a disease or disorder characterized by or induced by pathophysiological ligands of RAGE, for example missfolded proteins like amyloid &#x3b2; and advanced glycation-end-products.

Antibodies to receptor of advanced glycation end products (RAGE) and uses thereof

The present application relates to isolated proteins, particularly monoclonal antibodies, in particular CDR-grafted, humanized antibodies which bind to RAGE protein. Specifically, these antibodies have the ability to inhibit the binding of RAGE to its various ligands. The antibodies or portions thereof of described in the present application are useful for treating a disease or disorder characterized by or induced by pathophysiological ligands of RAGE, for example misfolded proteins like amyloid &#x3b2; and advanced glycation-end-products.

The subject invention relates to the cloning, expression and isolation of recombinant forms of beta-amyloid protein containing a N-terminal methionine (or one or more amino acids) as well as to methods of using this recombinant protein in the production of therapeutic antibodies, in the identification of therapeutic small molecules, and in the performance of diagnostic assays.

Methods of preparation of recombinant forms of human beta-amyloid protein and uses of these proteins

Growing community of inventors

Lake Zurich, IL, United States of America

John E Harlan